Literature DB >> 19394559

What a vascular surgeon should know and do about atherosclerotic risk factors.

Christos D Liapis1, Efthimios D Avgerinos, Nikolaos P Kadoglou, John D Kakisis.   

Abstract

Atherosclerosis is a systematic disease presenting with a significant overlapping of cardiovascular disorders implicating coronary heart disease and its equivalents, peripheral arterial disease, carotid arterial disease, and aneurysm disease. Evaluating patient's atherosclerotic risk profile is essential to guide primary and secondary prevention. Atherosclerotic risk factor modifications reduce, significantly, cardiovascular disease mortality and morbidity, particularly in high-risk patients. This article provides a reference guide for all conventional (eg, smoking, dyslipidemia, hypertension) and evolving (eg, homocysteine, C-reactive protein, fibrinogen, inflammatory markers) risk factors of atherosclerosis and recommends the currently effective strategies for an overall cardiovascular risk reduction. As vascular surgeons, by definition, conduct the overall management of patients with vascular disease understanding of the development, assessment, and management of atherosclerotic risk factors should remain among their highest priorities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394559     DOI: 10.1016/j.jvs.2008.12.046

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  Early detection of lesions of dorsal artery of foot in patients with type 2 diabetes mellitus by high-frequency ultrasonography.

Authors:  Yanrong Zhang; Wenjing Li; Tianwei Yan; Chengfa Lu; Xiang Zhou; Yan Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

Review 2.  Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

Authors:  Michael J Osgood; David G Harrison; Kevin W Sexton; Kyle M Hocking; Igor V Voskresensky; Padmini Komalavilas; Joyce Cheung-Flynn; Raul J Guzman; Colleen M Brophy
Journal:  Ann Vasc Surg       Date:  2012-03-22       Impact factor: 1.466

Review 3.  NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation.

Authors:  Zhilei Wang; Guang Xu; Zhiyong Li; Xiaohe Xiao; Jianyuan Tang; Zhaofang Bai
Journal:  J Inflamm Res       Date:  2022-01-19

4.  Comparable mid-term survival in patients undergoing elective fenestrated endovascular aneurysm repair and endovascular aneurysm repair for abdominal aortic aneurysm.

Authors:  Sofia Nessvi; Anders Gottsäter; Stefan Acosta
Journal:  SAGE Open Med       Date:  2014-01-28

5.  Activation of NLRP3 Inflammasome Promotes Foam Cell Formation in Vascular Smooth Muscle Cells and Atherogenesis Via HMGB1.

Authors:  Rui Wang; Weibin Wu; Wen Li; Shuichuan Huang; Zilun Li; Ruiming Liu; Zhen Shan; Chunxiang Zhang; Wen Li; Shenming Wang
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.